The biggest losers of the session on the Wall Street include Arcus Biosciences, Inc. (NYSE:RCUS), which fell -0.42 points or -4.23% to trade at $9.51 as last check. The stock closed last session at $9.93 and sets an active trading volume day with a reported 120415 contracts so far this session. RCUS shares had a relatively better volume day versus average trading capacity of 97.94 million shares, but with a 33.43 million float and a -9.73% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for RCUS stock indicates that the average analyst price target is $20.2 per share. This means the stock has a potential increase of 112.41% from where the RCUS share price has been trading recently which is between $9.7 and $10.18. There are some brokerage firms that offer lower targets than the average, with one of them, even setting their price target at $15.
The most recent news story about the stock that appeared in Yahoo Finance‘s news section was titled “Is Arcus Biosciences, Inc. (RCUS) A Good Stock To Buy?” and dated May 09, 2019.
Looking at the current readings for Arcus Biosciences, Inc., the two-week RSI stands at 35.38. This figure suggests that RCUS stock, for now, is neutral, meaning that the shares are stable in terms of price movement. The stochastic readings, on the other hand, based on the current RCUS readings is similarly very revealing as it has a stochastic reading of 26.36% at this stage. This figure means that RCUS share price today is being overbought.
Technical chart claims that Arcus Biosciences, Inc. (RCUS) would settle between $10.17/share to $10.42/share level. However, if the stock price goes below the $9.69 mark, then the market for Arcus Biosciences, Inc. becomes much weaker. If that happens, the stock price might even plunge as low as $9.46 for its downside target. The stock is currently in the red zone of MACD, with the indicator reading -0.61. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.
Analysts at Wedbush, assumed coverage of RCUS assigning Outperform rating, according to their opinion released on October 09. Leerink Partners, analysts launched coverage of Arcus Biosciences, Inc. (NYSE:RCUS) stock with a Outperform recommendation, according to their flash note issued to investors on April 09. Analysts at Goldman, made their first call for the equity with a Neutral recommendation, according to a research note that dated back to April 09.
RCUS equity has an average rating of 1.4, with the figure leaning towards a bullish end. 5 analysts who tracked the company were contacted by Reuters. Amongst them, 1 rated the stock as a hold while the remaining 4 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while no rated it as a sell. 4 analysts rated Arcus Biosciences, Inc. (NYSE:RCUS) as a buy or a strong buy while not a single analyst advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.
Arcus Biosciences, Inc. (RCUS)’s current-quarter revenues are projected to climb by nearly 263.2% to hit $4.54 million, based on current Zacks Consensus Estimate. The firm’s full-year revenues are expected to expand by over 9.54% from $8.35 million to a noteworthy $9.15 million. At the other end of the current quarter income statement, Arcus Biosciences, Inc. is expected to see its adjusted earnings surge by roughly -15.63% to hit $-0.37 per share. For the fiscal year, RCUS’s earnings are projected to climb by roughly -14.69% to hit $-1.64 per share.